行情

INCY

INCY

因塞特医疗
NASDAQ

实时行情|Nasdaq Last Sale

75.73
+1.55
+2.09%
交易中 12:47 04/02 EDT
开盘
73.51
昨收
74.18
最高
76.15
最低
73.51
成交量
48.47万
成交额
--
52周最高
96.79
52周最低
62.48
市值
164.16亿
市盈率(TTM)
36.89
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INCY价格均价为90.73,最高价位121.00,最低价为74.00。

EPS

INCY 新闻

更多
  • These 3 Biotech Stocks Are Outperforming Their Peers Here's Why
  • Investor's Business Daily · 1小时前
  • Cancer startup raises $125M for Keytruda combo drug trial
  • American City Business Journals · 21小时前
  • Morgan Stanley Upgrades Incyte to Overweight, Raises Price Target to $90
  • Benzinga · 1天前
  • Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
  • Seeking Alpha - Article · 1天前

所属板块

生物技术和医学研究
+2.05%
制药与医学研究
+1.62%

热门股票

代码
价格
涨跌幅

INCY 简况

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
展开

微牛提供Incyte Corporation(NASDAQ-INCY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INCY股票新闻,以帮助您做出投资决策。